EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Evaluation of Neurotrophic Receptor Tyrosine Kinase (NTRK) Alterations in Neuroblastomas

Nuriya Ismayil, Sefayi Merve Özdemir, Tekincan Çağrı Aktaş, Özde Elif Gökbayrak, Aylin Erol, Deniz Kızmazoğlu, Safiye Aktaş

Frontiers in Bioscience-Scholar · 23.03.2026 · 18 (1)

DOI: 10.31083/fbs46963 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Bioscience-Scholar, online erschienen am 23.03.2026. Verfasst von Nuriya Ismayil und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic Oncology, Oncology Institute, Dokuz Eylül University, 35330 İzmir, Turkey. Hauptthemen laut MEDLINE: Neuroblastoma, Receptor, trkA, Receptor, trkC, Receptor, trkB. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Turkish Pediatric Oncology Group Association 2024 Research Projects Support Program, Dokuz Eylül University Scientific Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Neuroblastoma (NB) is the most common extracranial solid tumor among pediatric cancers and accounts for approximately 15% of childhood cancer-related deaths. Neurotrophic receptor tyrosine kinases (NTRKs) are genes that play critical roles in the development and function of the nervous system. Therefore, elucidating the role of NTRKs in NB is important for both understanding basic biological mechanisms and developing novel therapeutic approaches. Specifically, NTRK fusions are being investigated as potential biomarkers and therapeutic targets for targeted therapy strategies. The tumor-agnostic TRK inhibitors larotrectinib and entrectinib are used to treat advanced or metastatic solid tumors with NTRK gene fusions. Accordingly, this study aimed to investigate the clinical significance of NTRK1, NTRK2, and NTRK3 point mutations, gene fusions, and protein expression, and to assess the effectiveness of these in guiding targeted therapy decisions in NB.

Methods

This study investigated pan-TRK expression, point mutations, and fusions in the NTRK1, NTRK2, and NTRK3 genes using next-generation sequencing (NGS) on paraffin-embedded blocks from 173 patients diagnosed with NB. Findings were analyzed in SPSS 29.0 using clinical data, MYCN amplification, and 11q deletion status, with Pearson correlation analysis applied at the p < 0.05 significance level.

Results

Immunohistochemistry (IHC) for NTRK revealed that 67.9% of cases were NTRK-positive. NGS analysis identified NTRK1 missense point mutations in 20 cases, NTRK2 in 9 cases, and NTRK3 in 9 cases. In addition, 5 fusions were detected in 4 of the 103 patients who underwent fusion analysis.

Conclusions

Owing to the presence of neural tissue, NTRKs are highly positive in IHC, making these genes unsuitable as biomarkers for assessing NTRK inhibitor sensitivity and resistance, which are tissue-agnostic drugs. The observed low fusion rate is consistent with the literature, and the significance of the numerous point mutations identified as agnostic markers warrants further investigation. NTRK expression, fusion, and point mutations were not associated with clinical parameters or survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuroblastomaReceptor, trkAReceptor, trkCReceptor, trkBMembrane GlycoproteinsHumansPoint MutationFemaleProtein Kinase InhibitorsMalePyrazolesPyrimidinesBenzamidesHigh-Throughput Nucleotide SequencingIndazolesChildBiomarkers, TumorChild, PreschoolInfant

Stichwörter der Autor:innen

gene fusionneuroblastomaneurotrophic receptor tyrosine kinasepoint mutation

Substanzen

Receptor, trkAReceptor, trkCNTRK3 protein, humanReceptor, trkBNTRK1 protein, humanMembrane Glycoproteinstropomyosin-related kinase-B, humanentrectinibProtein Kinase Inhibitorslarotrectinib

Autor:innen und Institutionen

  • Department of Basic Oncology, Oncology Institute, Dokuz Eylül University, 35330 İzmir, Turkey.
  • Department of Pharmacology, Ege Üniversity, 35000 İzmir, Turkey.
  • Department of Pediatric Oncology, Oncology Institute, Dokuz Eylül University, 35330 İzmir, Turkey.

Förderung

  • Turkish Pediatric Oncology Group Association 2024 Research Projects Support Program
  • Dokuz Eylül University Scientific Research Council

Zitieren

APA

Ismayil, N., Özdemir, S. M., Aktaş, T. Ç., Gökbayrak, Ö. E., Erol, A., Kızmazoğlu, D., & Aktaş, S. (2026). The Evaluation of Neurotrophic Receptor Tyrosine Kinase (NTRK) Alterations in Neuroblastomas. Frontiers in Bioscience-Scholar, 18(1). https://doi.org/10.31083/fbs46963

Vancouver

Ismayil N, Özdemir SM, Aktaş TÇ, Gökbayrak ÖE, Erol A, Kızmazoğlu D, et al. The Evaluation of Neurotrophic Receptor Tyrosine Kinase (NTRK) Alterations in Neuroblastomas. Frontiers in Bioscience-Scholar. 2026;18(1). doi:10.31083/fbs46963

BibTeX
@article{Ismayil2026,
  author = {Ismayil, Nuriya and Özdemir, Sefayi Merve and Aktaş, Tekincan Çağrı and Gökbayrak, Özde Elif and Erol, Aylin and Kızmazoğlu, Deniz and Aktaş, Safiye},
  title = {The Evaluation of Neurotrophic Receptor Tyrosine Kinase (NTRK) Alterations in Neuroblastomas},
  journal = {Frontiers in Bioscience-Scholar},
  year = {2026},
  volume = {18},
  number = {1},
  doi = {10.31083/fbs46963}
}
Kostenlos starten →